Kit Lu is an Oncology physician affiliated with UPMC Central Pa. OpenAlex indexes 45 publications with 371 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4300 Londonderry Rd
Med Science Pavillion Ste 302
Harrisburg, PA 171095317
Telephone
717-724-6780Provider last certified this registry record 5 Feb 2021.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202568 payments$99,807openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year202547 payments$58,983openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202544 payments$40,978openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.5%Aromatase Inhibitor72.3%Anastrozole86%Letrozole11%Exemestane3%Part D≥317 patientsKinase inhibitor7.1%Verzenio44%Ibrance35%Kisqali21%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
8.3%Serotonin-3 Receptor Antagonist3.5%Ondansetron Hcl100%Part D≥32 patientsPotassium supplement2.3%Potassium Chloride100%Part D<11 patients+ 2 more classes in this area
Nervous system
4.6%Gabapentinoids2.6%Gabapentin100%Part D<11 patientsPhenothiazine2%Prochlorperazine Maleate100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rates of inadequate ovarian suppression in premenopausal breast cancer patients receiving ovarian function suppression.
Journal of Clinical Oncology
2026 - Predictors of progression, survival, and psychosocial burden in early-stage breast cancer: A real-world cohort study.
Journal of Clinical Oncology
2026 - Financial De-Escalation in T1 Breast Cancers With the Low Magee Equation: An Experience From A Single Institution Without Genomic Testing
European Journal of Breast Health
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Hemal Gada, MD
UPMC Central Pa
David Weksberg, MD
UPMC Central Pa
William Beutler, MD
UPMC Central Pa
Mark Jarowenko, MD
UPMC Central Pa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”